Market Overview:
The global trigeminal neuralgia therapeutics market is expected to register a CAGR of 7.5% during the forecast period, 2018-2030. The market growth can be attributed to the increasing prevalence of trigeminal neuralgia and rising demand for better treatment options. Based on type, the neurorelease TN segment is expected to account for a major share of the global trigeminal neuralgia therapeutics market in 2018. This can be attributed to its high efficacy and safety profile as compared to other treatment options available in the market. Based on application, hospital segment is estimated to account for a major share of the global trigeminal neuralgia therapeutics market in 2018. This can be attributed to increasing number of hospital admissions owing to rising incidence rate of trigeminal neuralgia across the globe.
Product Definition:
Trigeminal neuralgia is a condition that affects the trigeminal nerve, which carries sensations from your face to your brain. Trigeminal neuralgia causes episodes of sudden, intense pain in one or more of the areas served by the trigeminal nerve: cheek, jaw, gums, teeth on one side of your mouth, and forehead.
NeuroRelease TN:
NeuroRelease TN is a drug that is developed by the German pharmaceutical company, Eisai Co. Ltd. The drug has been approved in Europe and Japan for the treatment of trigeminal neuralgia, also known as tGN orTN; it’s used to treat chronic facial pain caused by neuropathy in the brain or spine.
Onabotulinumtoxin A:
Onabotulinumtoxin A is a neurotoxin that belongs to the botulinum toxin family. It was discovered by chance in the early 1990s and has been used ever since in various medical applications such as for cervical dystonia, spasticity due to multiple sclerosis, and other movement disorders.
Application Insights:
Based on application, the global market is segmented into hospital-based, clinic-based and others. Hospital based was the largest segment in 2017 owing to factors such as increasing prevalence of migraine and growing awareness about treatment options. OnabotulinumtoxinA is most commonly used for trigeminal neuralgia at hospitals due to easy availability of healthcare professionals skilled in its administration.
The others segment includes pain clinics, neurology clinics and other peripheral facilities that treat patients with neurogenic pain disorders including facial Pain/Neurological Pain (TN/NP) or limb pain associated with spinal cord injuries or brain injury not related to the face or head region. Growing number of patients suffering from chronic TN are driving this segment which is expected to grow at a lucrative rate during the forecast period owing to high unmet medical needs across various settings globally coupled with rising incidence rates globally over recent years.
Regional Analysis:
North America dominated the global market in 2017. The presence of key players, favorable reimbursement policies, and increasing prevalence of chronic conditions are some factors responsible for its growth. In addition, the availability of a wide range of treatment options is expected to drive regional demand during the forecast period.
Asia Pacific is anticipated to witness lucrative CAGR over the forecast period owing to rising healthcare expenditure by governments and private sectors in economies such as China and India. Moreover, growing awareness about trigeminal neuralgia treatment options among patients is likely to support regional growth during the same period. Major companies are also focusing on expanding their presence in this region through mergers & acquisitions or strategic partnerships with local firms that offer cost-effective services for patients across Asia Pacific region (Southeast Asian countries).
Growth Factors:
- Increasing incidence of trigeminal neuralgia
- Growing awareness about trigeminal neuralgia and its treatment options
- Rising demand for better and more effective treatments for trigeminal neuralgia
- Availability of new and innovative therapies for trigeminal neuralgia
- Growing number of clinical studies on trigeminal neuralgia
Scope Of The Report
Report Attributes
Report Details
Report Title
Trigeminal Neuralgia Therapeutics Market Research Report
By Type
NeuroRelease TN, Onabotulinumtoxin A, Oxytocin, Raxatrigine Hydrochloride, U-2902, Others
By Application
Hospital, Clinic, Others
By Companies
Allergan, Inc., Biogen, Inc., Kineta, Inc., Merz Pharma GmbH & Co. KgaA, Trigemina, Inc.
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
243
Number of Tables & Figures
171
Customization Available
Yes, the report can be customized as per your need.
Global Trigeminal Neuralgia Therapeutics Market Report Segments:
The global Trigeminal Neuralgia Therapeutics market is segmented on the basis of:
Types
NeuroRelease TN, Onabotulinumtoxin A, Oxytocin, Raxatrigine Hydrochloride, U-2902, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Allergan, Inc.
- Biogen, Inc.
- Kineta, Inc.
- Merz Pharma GmbH & Co. KgaA
- Trigemina, Inc.
Highlights of The Trigeminal Neuralgia Therapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- NeuroRelease TN
- Onabotulinumtoxin A
- Oxytocin
- Raxatrigine Hydrochloride
- U-2902
- Others
- By Application:
- Hospital
- Clinic
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Trigeminal Neuralgia Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Trigeminal neuralgia (TN) is a rare, chronic pain condition that affects the trigeminal nerve, which is responsible for sensation in the face and head. TN can be caused by a variety of factors, including trauma or infection. Treatment typically involves medications and/or surgery to relieve pain.
Some of the key players operating in the trigeminal neuralgia therapeutics market are Allergan, Inc., Biogen, Inc., Kineta, Inc., Merz Pharma GmbH & Co. KgaA, Trigemina, Inc..
The trigeminal neuralgia therapeutics market is expected to grow at a compound annual growth rate of 7.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Trigeminal Neuralgia Therapeutics Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Trigeminal Neuralgia Therapeutics Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Trigeminal Neuralgia Therapeutics Market - Supply Chain
4.5. Global Trigeminal Neuralgia Therapeutics Market Forecast
4.5.1. Trigeminal Neuralgia Therapeutics Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Trigeminal Neuralgia Therapeutics Market Size (000 Units) and Y-o-Y Growth
4.5.3. Trigeminal Neuralgia Therapeutics Market Absolute $ Opportunity
5. Global Trigeminal Neuralgia Therapeutics Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Trigeminal Neuralgia Therapeutics Market Size and Volume Forecast by Type
5.3.1. NeuroRelease TN
5.3.2. Onabotulinumtoxin A
5.3.3. Oxytocin
5.3.4. Raxatrigine Hydrochloride
5.3.5. U-2902
5.3.6. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Trigeminal Neuralgia Therapeutics Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Trigeminal Neuralgia Therapeutics Market Size and Volume Forecast by Application
6.3.1. Hospital
6.3.2. Clinic
6.3.3. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Trigeminal Neuralgia Therapeutics Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Trigeminal Neuralgia Therapeutics Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Trigeminal Neuralgia Therapeutics Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Trigeminal Neuralgia Therapeutics Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Trigeminal Neuralgia Therapeutics Demand Share Forecast, 2019-2026
9. North America Trigeminal Neuralgia Therapeutics Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Trigeminal Neuralgia Therapeutics Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Trigeminal Neuralgia Therapeutics Market Size and Volume Forecast by Application
9.4.1. Hospital
9.4.2. Clinic
9.4.3. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Trigeminal Neuralgia Therapeutics Market Size and Volume Forecast by Type
9.7.1. NeuroRelease TN
9.7.2. Onabotulinumtoxin A
9.7.3. Oxytocin
9.7.4. Raxatrigine Hydrochloride
9.7.5. U-2902
9.7.6. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Trigeminal Neuralgia Therapeutics Demand Share Forecast, 2019-2026
10. Latin America Trigeminal Neuralgia Therapeutics Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Trigeminal Neuralgia Therapeutics Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Trigeminal Neuralgia Therapeutics Market Size and Volume Forecast by Application
10.4.1. Hospital
10.4.2. Clinic
10.4.3. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Trigeminal Neuralgia Therapeutics Market Size and Volume Forecast by Type
10.7.1. NeuroRelease TN
10.7.2. Onabotulinumtoxin A
10.7.3. Oxytocin
10.7.4. Raxatrigine Hydrochloride
10.7.5. U-2902
10.7.6. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Trigeminal Neuralgia Therapeutics Demand Share Forecast, 2019-2026
11. Europe Trigeminal Neuralgia Therapeutics Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Trigeminal Neuralgia Therapeutics Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Trigeminal Neuralgia Therapeutics Market Size and Volume Forecast by Application
11.4.1. Hospital
11.4.2. Clinic
11.4.3. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Trigeminal Neuralgia Therapeutics Market Size and Volume Forecast by Type
11.7.1. NeuroRelease TN
11.7.2. Onabotulinumtoxin A
11.7.3. Oxytocin
11.7.4. Raxatrigine Hydrochloride
11.7.5. U-2902
11.7.6. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Trigeminal Neuralgia Therapeutics Demand Share, 2019-2026
12. Asia Pacific Trigeminal Neuralgia Therapeutics Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Trigeminal Neuralgia Therapeutics Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Trigeminal Neuralgia Therapeutics Market Size and Volume Forecast by Application
12.4.1. Hospital
12.4.2. Clinic
12.4.3. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Trigeminal Neuralgia Therapeutics Market Size and Volume Forecast by Type
12.7.1. NeuroRelease TN
12.7.2. Onabotulinumtoxin A
12.7.3. Oxytocin
12.7.4. Raxatrigine Hydrochloride
12.7.5. U-2902
12.7.6. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Trigeminal Neuralgia Therapeutics Demand Share, 2019-2026
13. Middle East & Africa Trigeminal Neuralgia Therapeutics Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Trigeminal Neuralgia Therapeutics Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Trigeminal Neuralgia Therapeutics Market Size and Volume Forecast by Application
13.4.1. Hospital
13.4.2. Clinic
13.4.3. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Trigeminal Neuralgia Therapeutics Market Size and Volume Forecast by Type
13.7.1. NeuroRelease TN
13.7.2. Onabotulinumtoxin A
13.7.3. Oxytocin
13.7.4. Raxatrigine Hydrochloride
13.7.5. U-2902
13.7.6. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Trigeminal Neuralgia Therapeutics Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Trigeminal Neuralgia Therapeutics Market: Market Share Analysis
14.2. Trigeminal Neuralgia Therapeutics Distributors and Customers
14.3. Trigeminal Neuralgia Therapeutics Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Allergan, Inc.
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Biogen, Inc.
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Kineta, Inc.
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Merz Pharma GmbH & Co. KgaA
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Trigemina, Inc.
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. COMPANY6
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. COMPANY7
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
